Stoke Therapeutics, Inc. (NASDAQ:STOK) Stake Lifted by RTW Investments LP

RTW Investments LP increased its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 10.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,652,285 shares of the company's stock after buying an additional 427,447 shares during the quarter. RTW Investments LP owned about 8.78% of Stoke Therapeutics worth $57,177,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Lynx1 Capital Management LP raised its holdings in shares of Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company's stock worth $70,052,000 after purchasing an additional 1,488,371 shares during the period. Assenagon Asset Management S.A. purchased a new position in Stoke Therapeutics in the second quarter valued at approximately $19,835,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock valued at $18,741,000 after buying an additional 1,123,500 shares in the last quarter. Logos Global Management LP purchased a new stake in Stoke Therapeutics during the second quarter worth approximately $14,186,000. Finally, Marshall Wace LLP increased its position in shares of Stoke Therapeutics by 550.1% in the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company's stock worth $15,686,000 after acquiring an additional 982,451 shares in the last quarter.

Stoke Therapeutics Price Performance

STOK traded down $0.24 on Thursday, reaching $12.57. The company's stock had a trading volume of 719,683 shares, compared to its average volume of 747,994. Stoke Therapeutics, Inc. has a 1 year low of $4.09 and a 1 year high of $17.58. The business's 50 day moving average is $12.39 and its 200 day moving average is $13.74. The stock has a market cap of $665.83 million, a price-to-earnings ratio of -5.99 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. As a group, research analysts forecast that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the transaction, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Skorpios Trust sold 1,937,500 shares of the company's stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total value of $27,221,875.00. Following the sale, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 17.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. Leerink Partnrs upgraded Stoke Therapeutics to a "strong-buy" rating in a research note on Friday, October 11th. Finally, Leerink Partners began coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an "outperform" rating and a $18.00 price target on the stock. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $20.83.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.